Uric Acid is a neuroprotectant and cerebral reperfusion enhancer identified by Dr Ángel Chamorro at the Hospital Clínic Barcelona and transferred to FreeOx Biotech for its development as a drug, Ox-01, which has been granted a patent in the USA for its use in combination with Mechanical Thrombectomy in ischaemic stroke.
Now, uric acid was shown to improve the prognosis of ischaemic stroke in a preclinical study carried out on rodents within the framework of the Stroke Preclinical Assessment Network (SPAN) in the USA, a network of experimental laboratories focusing on cerebral ischaemia, coordinated by the Keck School of Medicine of the University of Southern California (USC). The results of the study were presented at the International Stroke Conference held last week in Dallas.
Uric Acid had already demonstrated clinical benefit in stroke patients treated with mechanical thrombectomy in a clinical trial led by Dr Ángel Chamorro, head of the IDIBAPS-Hospital Clínic Barcelona Cerebrovascular Pathology Unit, scientific advisor at FreeOx Biotech, Assistant Professor at the University of Iowa and participant in the SPAN network study. “The SPAN study was carried out in animal models of ischaemic stroke, in experimental conditions with the maximum methodological rigour, which positions Uric Acid and FreeOx in an advantageous position for the clinical validation of Ox-01 in an upcoming pivotal clinical trial in stroke patients treated with mechanical thrombectomy”, says Dr Chamorro.
Likewise, Dr Tudor Jovin, scientific co-founder of FreeOx Biotech, points out that “the SPAN results represent one of the most important findings in recent years in terms of identifying new treatments for ischaemic stroke”.
“The positive results of the preclinical study are a very important step to ensure Ox-01 reaches patients as soon as possible”, comments Carlos Lurigados, CEO of FreeOx Biotech.
Dr Ángel Chamorro and Carlos Lurigados, co-founders of FreeOx Biotech
Comments